- Global Expanded Access Program for Pemigatinib in Patients with Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma and Fibroblast Growth Factor Receptor Gene Alterations
-
Lindley A, Prager G, Bitzer M, Burn TC, Lihou CF, Croft E
- KMID: 2557671
- Cancer Res Treat.
- 2024 Jul;56(3):847-855.
- doi: 10.4143/crt.2023.1197
Purpose Pemigatinib is a fibroblast growth factor receptor-2 (FGFR2) inhibitor approved for use in patients with previously treated cholangiocarcinoma (CCA) and FGFR2 fusions or rearrangements. This ongoing global Expanded Access... -
- CITED
-
- Close
- SHARE
-
- Close
